Diffuse Large B-Cell Lymphoma (DLBCL): New Treatment Approaches for Relapsed Refractory DLBCL

Listen Now

Topics Covered

• Overview of Diffuse Large B-Cell Lymphoma (DLBCL), Including Staging and Grading, In the Context of COVID, Seasonal Flu and RSV
• Current Standard of Care, New & Emerging Treatment Approaches
• Treatment Options for Relapsed Refractory DLBCL, Including Bispecific Antibodies
• Understanding How Bispecific Antibodies Work in the Treatment of Relapsed Refractory DLBCL
• The Role of Clinical Trials: How Research Contributes to Treatment Options
• Tips to Prevent & Manage Treatment Side Effects, Symptoms, Discomfort & Pain
• Talking with Your Health Care Team about Quality-of-Life Concerns
• Guidelines to Prepare for Telehealth/Telemedicine Appointments, Including Technology, Prepared List of Questions & Discussion of OpenNotes
• Questions for Our Panel of Experts

Our Panel of Experts

Catherine S M Diefenbach, MD

Associate Professor of Medicine, Translational Director of Hematology, Director Clinical Lymphoma, Perlmutter Cancer Center, An NCI-designated Comprehensive Cancer Center, NYU Langone Health

Belita Cowan, MA

President, Lymphoma Foundation of America

Carolyn Messner, DSW, BCD, FAPOS, FAOSW

Senior Director of Education and Training, CancerCare

Brochure

You can download the brochure for this workshop

Workshop Date

This workshop was originally recorded on June 20, 2024.